All News

Global Graves Disease Treatment Market­ Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast 2026


Global Graves disease treatment market­ is expected to grow at a steady CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. The key market players in the global graves disease treatment […]

Global Graves disease treatment market­ is expected to grow at a steady CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017.

The key market players in the global graves disease treatment market­ are Abbott, GlaxoSmithKline plc, ALLERGAN, Novartis AG, Merck & Co., Inc, Sanofi, Pfizer Inc, AbbVie Inc, Mylan N.V, Apitope, Merck KGaA, Amgen Inc, , Horizon Therapeutics plc, Medtronic, Immunovant, Inc, among others

Ask For Complimentary Sample PDF| Request At

The study objectives of this report are:

  • To analyze global Graves Disease Treatment status, future forecast, growth opportunity, key market and key players.
  • To present the Graves Disease Treatment development in United States, Europe and China.
  • To strategically profile the key players and comprehensively analyze their development plan and strategies.
  • To define, describe and forecast the market by product type, market and key regions.
  • The future aspects impacting the global Graves Disease Treatment market in every possible way are also further discussed in the report. The market providers compete on the basis of innovation, reputation, pricing, service, promotion and distribution. The Graves Disease Treatment market report has faced several phases after gathering the most important data from the research with facing the challenge of arranging it in a proper manner, which has made the analysis more efficient and effective.

Segmentation: Global Graves Disease Treatment Market­

By Mechanism of Action

(Anti-thyroid Agents, Beta Blockers, Corticosteroids and Others),


(Propylthiouracil, Methimazole, Propranolol, Prednisone and Others),


(Physical Exam, Blood Test, Radioactive Iodine Uptake Test, Ultrasound and Imaging Tests),


(Medication, Radioactive Iodine Therapy, Surgery and Others),

Route of Administration

(Oral, Intravenous and Others),

Distribution Channel

(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy),


(Hospitals, Homecare, Specialty Clinics, Others),


(North America, Europe, South America, Asia-Pacific, Middle East and Africa)

View detailed table of content @

Market Drivers

High prevalence of autoimmune diseases such as Grave’s disease and Hashimoto’s thyroiditis is driving the market growth

Various national health programs related to thyroid disease that raise awareness regarding such diseases further boosts the growth of this market

Favorable reimbursement policies for the treatment

Increasing iodine disorder and thyroid tumors screening is also fueling the market growth

Market Restraints

High costs associated with the treatment and the usage of alternative medicines for the treatment of thyroid disorders is hindering the market growth

Side-effects associated with the current medication also restricts the market growth

Stringent government regulations is hampering the market growth

Table Of Content:

Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Global Graves Disease Treatment Market Landscape

Part 04: Global Graves Disease Treatment Market Sizing

Part 05: Global Graves Disease Treatment Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape
Part 08: Geographic Landscape

Part 09: Decision Framework
Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

Inquiry For Customize Report With Discount at

Key Developments in the Market

In June 2019, Horizon Therapeutics plc is developing teprotumumab, a complex protein that works by inhibiting the insulin-like growth factor I receptor (IGF-1R) for the treatment of Graves disease, currently ongoing in phase lll of OPTIC l trial. With this development the company provides better solution for the treatment of graves disease

In June 2019, Apitope is developing a novel drug ATX-GD-59, a peptide mixture of two different, highly soluble apitopes derived from TSH-receptor for the treatment of Graves disease currently ongoing in phase l clinical trial. If approved it will become the first innovative treatment in more than 60 years and will provide potential treatment to target the immunological basis of Graves’ disease

Potentials held by the report

  1. Detailed overview of the market
  2. Key developments and product launches in the market
  3. Key parameters which are driving the market
  4. Strategies of key players and product offerings
  5. In-depth market segmentation

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.


Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]